You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Go to Close Top

Efficacy

Avamys is effective for major nasal and ocular symptoms associated with seasonal AR* 1

Running nose
Nasal symptoms
Eye
Ocular symptoms

Effective reduction in the nasal and ocular symptoms of perennial AR from baseline 2

Effective reduction in the nasal and ocular symptoms

Most AEs were of mild to moderate intensity and comparable to placebo. The most common AEs reported were: epistaxis, headache, nasopharyngitis, laryngopharyngeal pain.

The efficacy of FFNS for individual symptoms is consistent across different pollen allergy seasons, geographical locations, and ethnicity of the patients in SAR. 1

Targeted action with Avamys

Fluticasone furoate has the highest glucocorticoid receptor affinity and the strongest tissue binding compared to other INCS 3-5

Glucocorticoid receptor affinity 4 (in human lung tissue in vitro)

Glucocorticoid receptor affinity

* Integrated analysis performed on data from 4 randomised, double-blind, placebo-controlled, parallel-group, multicentre trials, which were designed to evaluate the efficacy and safety of FFNS for 14 days in 1141 adult and adolescent seasonal AR patients. The primary efficacy measure for each study was the mean change from baseline over the entire treatment period in daily rTNSS.

† Global, randomised, double-blind, placebo-controlled, 6-week study evaluating the efficacy and tolerability of intranasal fluticasone furoate in patients ≥12 years of age (n=302) with perennial AR. The primary efficacy measure was mean change from baseline over the 6-week treatment period in daily reflective TNSS.

References:

  1. Maspero JF, Walters RD, Wu W, et al. An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc. 2010;31(6):483-492.
  2. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313-321.
  3. Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540-1550.
  4. Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.
  5. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660-667.

Avamys is a registered trademark of the GlaxoSmithKline group of companies.